ZA200405015B - Use of sulfated glycosaminoglycans for establishing effective labor in women - Google Patents

Use of sulfated glycosaminoglycans for establishing effective labor in women Download PDF

Info

Publication number: ZA200405015B
Authority: ZA; South Africa
Prior art keywords: labor; sulfates; depolymerised; sulfate; glycosaminoglycan
Prior art date: 2002-01-02

Application number

ZA2004/05015A

Other languages

English (en)

Inventor

Ekman-Ordeberg Gunvor

Malmstrom Anders

Original Assignee

Dilafor Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-02

Filing date

2004-06-24

Publication date

2005-08-31

2004-06-24 Application filed by Dilafor Ab filed Critical Dilafor Ab

2005-08-31 Publication of ZA200405015B publication Critical patent/ZA200405015B/en

Links

229920002683 Glycosaminoglycan Polymers 0.000 title claims description 34
229920002971 Heparan sulfate Polymers 0.000 claims description 22
229920000669 heparin Polymers 0.000 claims description 20
229960002897 heparin Drugs 0.000 claims description 20
230000014508 negative regulation of coagulation Effects 0.000 claims description 15
229920000045 Dermatan sulfate Polymers 0.000 claims description 12
229920001287 Chondroitin sulfate Polymers 0.000 claims description 10
210000003679 cervix uteri Anatomy 0.000 claims description 9
MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 8
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 6
101800000989 Oxytocin Proteins 0.000 claims description 6
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims description 6
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 6
229960001723 oxytocin Drugs 0.000 claims description 6
239000000825 pharmaceutical preparation Substances 0.000 claims description 5
229940107200 chondroitin sulfates Drugs 0.000 claims description 4
210000000754 myometrium Anatomy 0.000 claims description 4
230000037452 priming Effects 0.000 claims description 3
230000000699 topical effect Effects 0.000 claims description 3
238000009109 curative therapy Methods 0.000 claims description 2
230000000069 prophylactic effect Effects 0.000 claims description 2
238000002360 preparation method Methods 0.000 description 22
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 9
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 8
229940051593 dermatan sulfate Drugs 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
239000002253 acid Substances 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
150000002016 disaccharides Chemical group 0.000 description 7
239000002244 precipitate Substances 0.000 description 7
230000005070 ripening Effects 0.000 description 7
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 6
229940059329 chondroitin sulfate Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 6
150000004676 glycans Polymers 0.000 description 5
230000035935 pregnancy Effects 0.000 description 5
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
210000002744 extracellular matrix Anatomy 0.000 description 4
229940097043 glucuronic acid Drugs 0.000 description 4
238000000034 method Methods 0.000 description 4
230000032696 parturition Effects 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010053567 Coagulopathies Diseases 0.000 description 3
208000034423 Delivery Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102000016611 Proteoglycans Human genes 0.000 description 3
108010067787 Proteoglycans Proteins 0.000 description 3
230000002429 anti-coagulating effect Effects 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
230000035602 clotting Effects 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
229920002674 hyaluronan Polymers 0.000 description 3
229960003160 hyaluronic acid Drugs 0.000 description 3
230000008520 organization Effects 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
230000008569 process Effects 0.000 description 3
238000007634 remodeling Methods 0.000 description 3
238000005670 sulfation reaction Methods 0.000 description 3
238000012384 transportation and delivery Methods 0.000 description 3
230000013948 uterine smooth muscle contraction Effects 0.000 description 3
241000283690 Bos taurus Species 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
108010074860 Factor Xa Proteins 0.000 description 2
208000000091 Maternal Death Diseases 0.000 description 2
208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
229960001927 cetylpyridinium chloride Drugs 0.000 description 2
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
230000010339 dilation Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
210000004347 intestinal mucosa Anatomy 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
230000019635 sulfation Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
101800000414 Corticotropin Proteins 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
229920000288 Keratan sulfate Polymers 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
208000036365 Normal labour Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
208000006399 Premature Obstetric Labor Diseases 0.000 description 1
206010036595 Premature delivery Diseases 0.000 description 1
206010036877 Prolonged Pregnancy Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
108090000054 Syndecan-2 Proteins 0.000 description 1
206010046914 Vaginal infection Diseases 0.000 description 1
201000008100 Vaginitis Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
-1 amine amine Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002001 anti-metastasis Effects 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
229940127217 antithrombotic drug Drugs 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
239000001639 calcium acetate Substances 0.000 description 1
229960005147 calcium acetate Drugs 0.000 description 1
235000011092 calcium acetate Nutrition 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000037020 contractile activity Effects 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
238000003381 deacetylation reaction Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229940087051 fragmin Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000002301 glucosamine derivatives Chemical class 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
239000002634 heparin fragment Substances 0.000 description 1
150000008273 hexosamines Chemical class 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000003055 low molecular weight heparin Substances 0.000 description 1
229940127215 low-molecular weight heparin Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000002184 nasal cartilage Anatomy 0.000 description 1
239000002547 new drug Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
208000033300 perinatal asphyxia Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ZA2004/05015A 2002-01-02 2004-06-24 Use of sulfated glycosaminoglycans for establishing effective labor in women ZA200405015B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0200005A SE521676C2 (sv)	2002-01-02	2002-01-02	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
PCT/SE2003/000004 WO2003055499A1 (en)	2002-01-02	2003-01-02	Use of sulfated glycosaminoglycans for establishing effective labor in women

Publications (1)

Publication Number	Publication Date
ZA200405015B true ZA200405015B (en)	2005-08-31

Family

ID=20286575

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA2004/05015A ZA200405015B (en)	2002-01-02	2004-06-24	Use of sulfated glycosaminoglycans for establishing effective labor in women

Country Status (21)

Country	Link
US (3)	US7407945B2 ( )
EP (1)	EP1461049B1 ( )
JP (1)	JP4434741B2 ( )
KR (1)	KR100958691B1 ( )
CN (1)	CN100341518C ( )
AT (1)	ATE395067T1 ( )
AU (1)	AU2003201787B2 ( )
CA (1)	CA2472093C ( )
CY (1)	CY1108260T1 ( )
DE (1)	DE60320931D1 ( )
DK (1)	DK1461049T3 ( )
ES (1)	ES2306852T3 ( )
IL (2)	IL162664A0 ( )
NO (1)	NO332702B1 ( )
NZ (1)	NZ533856A ( )
PL (1)	PL206458B1 ( )
PT (1)	PT1461049E ( )
SE (1)	SE521676C2 ( )
SI (1)	SI1461049T1 ( )
WO (1)	WO2003055499A1 ( )
ZA (1)	ZA200405015B ( )

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE521676C2 (sv)	2002-01-02	2003-11-25	Dilafor Ab	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
WO2005007223A2 (en) *	2003-07-16	2005-01-27	Sasha John	Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
WO2013095215A1 (en)	2011-12-19	2013-06-27	Dilaforette Ab	Low anticoagulant heparins
PT2794665T (pt) *	2011-12-19	2018-01-24	Dilafor Ab	Glicosaminoglicanos não anticoagulativos que compreendem unidade repetitiva de dissacáridos e sua utilização médica
UA117908C2 (uk) *	2012-03-26	2018-10-25	Ділафор Аб	Застосування гепарину або гепарансульфату для індукції пологів
NZ631279A (en) *	2012-03-26	2016-06-24	Dilafor Ab	Method for treatment of labor arrest
MY192330A (en) *	2012-05-08	2022-08-17	Dilafor Ab	Treatment of postpartum haemorrhage with chemically modified heapin or heparan sulphate and a uterotonic agent
CA2879763C (en)	2012-08-03	2020-12-01	Simon LOWRY	The use of antithrombin in extracorporeal membrane oxygenation
CA3169421A1 (en)	2020-02-17	2021-08-26	Dilafor Ab	Tafoxiparin for the treatment of preeclampsia
US20230355658A1 (en)	2022-05-03	2023-11-09	Dilafor Ab	Medical use of tafoxiparin
EP4272749A1 (en)	2022-05-03	2023-11-08	Dilafor AB	New medical use of tafoxiparin

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5223263A (en) *	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
EP0209924A1 (en) *	1985-07-12	1987-01-28	Akzo N.V.	New anti-trombosis agent based on glycosaminoglycan, process for its preparation, and pharmaceutical compositions
US4916122A (en) *	1987-01-28	1990-04-10	University Of Georgia Research Foundation, Inc.	3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) *	1987-01-28	1993-03-02	University Of Georgia Research Foundation, Inc.	3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
SE8702254D0 (sv)	1987-05-29	1987-05-29	Kabivitrum Ab	Novel heparin derivatives
GB8719367D0 (en) *	1987-08-15	1987-09-23	Wellcome Found	Therapeutic compounds
US5968914A (en) *	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US6020322A (en) *	1993-11-09	2000-02-01	Pro-Neuron, Inc.	Acyl deoxyribonucleoside derivatives and uses thereof
US5470838A (en) *	1987-10-28	1995-11-28	Pro-Neuron, Inc.	Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5736531A (en) *	1987-10-28	1998-04-07	Pro-Neuron, Inc.	Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5411947A (en) *	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) *	1989-11-22	1993-03-16	Vical, Inc.	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5543389A (en) *	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization	Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) *	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
US5256641A (en) *	1990-11-01	1993-10-26	State Of Oregon	Covalent polar lipid-peptide conjugates for immunological targeting
US5149794A (en) *	1990-11-01	1992-09-22	State Of Oregon	Covalent lipid-drug conjugates for drug targeting
US5280016A (en)	1991-03-29	1994-01-18	Glycomed Incorporated	Non-anticoagulant heparin derivatives
US5554728A (en) *	1991-07-23	1996-09-10	Nexstar Pharmaceuticals, Inc.	Lipid conjugates of therapeutic peptides and protease inhibitors
SE9302135D0 (sv) *	1993-06-18	1993-06-18	Kabi Pharmacia Ab	New pharmaceutical composition
US5587362A (en) *	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
US5559101A (en) *	1994-10-24	1996-09-24	Genencor International, Inc.	L-ribofuranosyl nucleosides
DK0831852T3 (da) *	1995-06-07	2007-03-19	Univ Emory	Nukleosider med anti-hepatitis B-virusaktivitet
US6025335A (en) *	1995-09-21	2000-02-15	Lipitek International, Inc.	L-Nucleoside Dimer Compounds and therapeutic uses
US5767269A (en) *	1996-10-01	1998-06-16	Hamilton Civic Hospitals Research Development Inc.	Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
JP4203611B2 (ja) *	1996-10-15	2009-01-07	生化学工業株式会社	子宮頸管熟化剤
JP4412756B2 (ja)	1998-02-26	2010-02-10	生化学工業株式会社	新規多糖誘導体、その製造法及びそれを有効成分とする医薬組成物
BR9911457A (pt) *	1998-06-24	2001-12-11	Univ Emory	Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv
IL127896A0 (en) *	1998-12-31	1999-10-28	Gail Laster	A novel treatment for preeclampsia and related diseases
JP2000309544A (ja) *	1999-02-25	2000-11-07	Seikagaku Kogyo Co Ltd	早産または流産防止剤および子宮頚管熟化抑制剤ならびにヒアルロニダーゼの阻害剤
SE521676C2 (sv)	2002-01-02	2003-11-25	Dilafor Ab	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet

2002
- 2002-01-02 SE SE0200005A patent/SE521676C2/sv unknown
2003
- 2003-01-02 PT PT03700633T patent/PT1461049E/pt unknown
- 2003-01-02 AU AU2003201787A patent/AU2003201787B2/en not_active Ceased
- 2003-01-02 EP EP03700633A patent/EP1461049B1/en not_active Expired - Lifetime
- 2003-01-02 NZ NZ53385603A patent/NZ533856A/xx not_active IP Right Cessation
- 2003-01-02 CN CNB038019442A patent/CN100341518C/zh not_active Expired - Fee Related
- 2003-01-02 JP JP2003556076A patent/JP4434741B2/ja not_active Expired - Fee Related
- 2003-01-02 DE DE60320931T patent/DE60320931D1/de not_active Expired - Lifetime
- 2003-01-02 DK DK03700633T patent/DK1461049T3/da active
- 2003-01-02 KR KR1020047010488A patent/KR100958691B1/ko not_active Expired - Fee Related
- 2003-01-02 CA CA2472093A patent/CA2472093C/en not_active Expired - Fee Related
- 2003-01-02 AT AT03700633T patent/ATE395067T1/de active
- 2003-01-02 ES ES03700633T patent/ES2306852T3/es not_active Expired - Lifetime
- 2003-01-02 WO PCT/SE2003/000004 patent/WO2003055499A1/en not_active Ceased
- 2003-01-02 IL IL16266403A patent/IL162664A0/xx unknown
- 2003-01-02 PL PL370428A patent/PL206458B1/pl unknown
- 2003-01-02 SI SI200331314T patent/SI1461049T1/sl unknown
- 2003-01-02 US US10/500,284 patent/US7407945B2/en not_active Expired - Fee Related
2004
- 2004-06-21 IL IL162664A patent/IL162664A/en not_active IP Right Cessation
- 2004-06-24 ZA ZA2004/05015A patent/ZA200405015B/en unknown
- 2004-07-27 NO NO20043190A patent/NO332702B1/no not_active IP Right Cessation
2008
- 2008-07-07 US US12/168,683 patent/US8207145B2/en not_active Expired - Fee Related
- 2008-08-13 CY CY20081100861T patent/CY1108260T1/el unknown
2012
- 2012-05-09 US US13/467,918 patent/US8524688B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2472093A1 (en)	2003-07-10
US7407945B2 (en)	2008-08-05
AU2003201787B2 (en)	2008-02-28
PL370428A1 (en)	2005-05-30
NZ533856A (en)	2004-12-24
PT1461049E (pt)	2008-08-22
US20080269165A1 (en)	2008-10-30
KR100958691B1 (ko)	2010-05-18
SI1461049T1 (sl)	2008-12-31
ES2306852T3 (es)	2008-11-16
SE521676C2 (sv)	2003-11-25
AU2003201787A1 (en)	2003-07-15
ATE395067T1 (de)	2008-05-15
SE0200005L (sv)	2003-07-03
US8524688B2 (en)	2013-09-03
SE0200005D0 (sv)	2002-01-02
HK1076389A1 (en)	2006-01-20
CN100341518C (zh)	2007-10-10
JP4434741B2 (ja)	2010-03-17
DK1461049T3 (da)	2008-09-15
IL162664A (en)	2009-06-15
US8207145B2 (en)	2012-06-26
DE60320931D1 (de)	2008-06-26
JP2005513148A (ja)	2005-05-12
CA2472093C (en)	2011-02-22
PL206458B1 (pl)	2010-08-31
CY1108260T1 (el)	2014-02-12
EP1461049A1 (en)	2004-09-29
NO332702B1 (no)	2012-12-10
KR20040075917A (ko)	2004-08-30
NO20043190L (no)	2004-07-26
IL162664A0 (en)	2005-11-20
US20120225843A1 (en)	2012-09-06
WO2003055499A1 (en)	2003-07-10
US20050075314A1 (en)	2005-04-07
CN1612741A (zh)	2005-05-04
EP1461049B1 (en)	2008-05-14

Publication	Publication Date	Title
US8524688B2 (en)	2013-09-03	Use of sulfated glycosaminoglycans for establishing effective labor in women
CA2856918C (en)	2017-07-04	Use of chemically modified heparin derivates in sickle cell disease
CN104244957B (zh)	2017-11-17	用于治疗分娩停止的方法
CN104203256B (zh)	2017-11-24	用于引产的包含硫酸化的葡糖胺聚糖的联合治疗
CA2868403A1 (en)	2013-11-14	Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
HK1076389B (en)	2008-01-25	Use of sulfated glycosaminoglycans for the manufacture of a pharmaceutical preparation for the prevention and treatment of slow progress of term labor
AU2012203519A1 (en)	2014-01-16	Treatment of cytokine mediated conditions
CA2779838A1 (en)	2013-12-14	Treatment of cytokine mediated conditions
HK1062524B (en)	2007-09-14	Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis
HK1199893B (en)	2018-09-14	Use of chemically modified heparin derivates in sickle cell disease